CN103237812A - Ephrin B2抗体及其应用 - Google Patents

Ephrin B2抗体及其应用 Download PDF

Info

Publication number
CN103237812A
CN103237812A CN2011800534643A CN201180053464A CN103237812A CN 103237812 A CN103237812 A CN 103237812A CN 2011800534643 A CN2011800534643 A CN 2011800534643A CN 201180053464 A CN201180053464 A CN 201180053464A CN 103237812 A CN103237812 A CN 103237812A
Authority
CN
China
Prior art keywords
polypeptide
antibody
ephrin
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800534643A
Other languages
English (en)
Chinese (zh)
Inventor
乔治·路易斯·马丁内斯托雷夸德拉达
玛丽亚·安赫莱斯·阿本格扎尔因方特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spanish National Cancer Research Centre
Original Assignee
Spanish National Cancer Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spanish National Cancer Research Centre filed Critical Spanish National Cancer Research Centre
Publication of CN103237812A publication Critical patent/CN103237812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800534643A 2010-09-21 2011-09-20 Ephrin B2抗体及其应用 Pending CN103237812A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201031402 2010-09-21
ES201031402A ES2378976B1 (es) 2010-09-21 2010-09-21 Anticuerpo contra ephrin b2 y su uso.
PCT/ES2011/070655 WO2012038573A1 (es) 2010-09-21 2011-09-20 Anticuerpo contra ephrin b2 y su uso

Publications (1)

Publication Number Publication Date
CN103237812A true CN103237812A (zh) 2013-08-07

Family

ID=45873482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800534643A Pending CN103237812A (zh) 2010-09-21 2011-09-20 Ephrin B2抗体及其应用

Country Status (12)

Country Link
US (1) US9062109B2 (enExample)
EP (1) EP2620449A4 (enExample)
JP (1) JP2013542720A (enExample)
KR (1) KR20140014062A (enExample)
CN (1) CN103237812A (enExample)
AU (1) AU2011306816A1 (enExample)
BR (1) BR112013005977A2 (enExample)
CA (1) CA2812727A1 (enExample)
ES (1) ES2378976B1 (enExample)
MX (1) MX2013003168A (enExample)
RU (1) RU2013118454A (enExample)
WO (1) WO2012038573A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477A (zh) * 2015-03-03 2015-06-10 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
CN113825770A (zh) * 2019-05-14 2021-12-21 善福德健康 抗人肝配蛋白b1抗体及其用途
CN121159668A (zh) * 2025-09-12 2025-12-19 北京威斯克生物医药有限公司 Ephrin-B2重组蛋白及其疫苗、制备方法和应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022516611A (ja) * 2018-12-28 2022-03-01 ザ ジェネラル ホスピタル コーポレイション 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
WO2020242910A1 (en) * 2019-05-24 2020-12-03 The Regents Of The University Ofcalifornia Compositions and methods for treating cancer
TW202547871A (zh) * 2024-03-27 2025-12-16 美商麥第爾醫療公司 抗ｅｐｈｒｉｎ ｂ２抗體及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101410413A (zh) * 2006-01-20 2009-04-15 健泰科生物技术公司 抗ephrinb2抗体及其使用方法
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
EP1954720A1 (en) * 2005-10-31 2008-08-13 The Government of the United States of America, as represented by the Secretary of Health and Human Services, National Institutes of Health Antibodies and immunotoxins that target human glycoprotein nmb
PL1972637T3 (pl) * 2007-03-19 2012-01-31 Univ Stuttgart Antagoniści selektywni wobec huTNFR1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101410413A (zh) * 2006-01-20 2009-04-15 健泰科生物技术公司 抗ephrinb2抗体及其使用方法
WO2010019565A2 (en) * 2008-08-12 2010-02-18 Medlmmune, Llc Anti-ephrin b2 antibodies and their use in treatment of disease

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694477A (zh) * 2015-03-03 2015-06-10 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
CN104694477B (zh) * 2015-03-03 2018-04-17 西安交通大学 一种EphrinB2高表达的重组HEK293细胞及其应用
CN113825770A (zh) * 2019-05-14 2021-12-21 善福德健康 抗人肝配蛋白b1抗体及其用途
CN121159668A (zh) * 2025-09-12 2025-12-19 北京威斯克生物医药有限公司 Ephrin-B2重组蛋白及其疫苗、制备方法和应用

Also Published As

Publication number Publication date
WO2012038573A1 (es) 2012-03-29
CA2812727A1 (en) 2012-03-29
KR20140014062A (ko) 2014-02-05
MX2013003168A (es) 2013-08-21
US9062109B2 (en) 2015-06-23
US20130287795A1 (en) 2013-10-31
EP2620449A1 (en) 2013-07-31
ES2378976B1 (es) 2013-05-06
RU2013118454A (ru) 2014-10-27
EP2620449A4 (en) 2014-03-26
JP2013542720A (ja) 2013-11-28
BR112013005977A2 (pt) 2019-09-24
AU2011306816A1 (en) 2013-04-04
ES2378976A1 (es) 2012-04-19

Similar Documents

Publication Publication Date Title
ES2899036T3 (es) Nanocuerpo anti-PD-L1 y su uso
US11292841B2 (en) Anti-PD-1 nano-antibody and application thereof
US11912770B2 (en) Blocking type PD-L1 single-domain camel antibody and application thereof
US10106609B2 (en) CD7 nanobodies, encoding sequence and use thereof
JP2021193150A (ja) 小細胞肺癌に対する標的療法
CN101820910B (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
US12391766B2 (en) Antibodies against N-acetylglucosamine and N-acetyl-galactosamine
Zeng et al. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer
Li et al. Generation of a high-affinity nanobody against CD147 for tumor targeting and therapeutic efficacy through conjugating doxorubicin
KR20170039074A (ko) Tmcc3의 억제에 의한 암 저해 방법
Martins et al. EphA3 CAR T cells are effective against glioblastoma in preclinical models
US9062109B2 (en) Anti-ephrin-B2 antibody and compositions comprising it
Niesen et al. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells
Li et al. A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells
CN110627905B (zh) 靶向vegf与egfr的双功能融合蛋白及其应用
ES2831651T3 (es) Uso de anticuerpos y antagonistas dirigidos contra Lrg1 en un tratamiento
US20210155709A1 (en) Antibodies anti tumor associated antigens and method for obtaining them
CN110734494B (zh) 抗tspan8单克隆抗体及其用途
CN120025443A (zh) 靶向cd33的全人源抗体
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
HK40110126A (en) Anti-trop2 single-domain antibody and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130807